regeneron_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
| Date of Report
(Date of earliest event reported): May 13, 2010 (May 12,
2010) |
| REGENERON PHARMACEUTICALS,
INC. |
| (Exact Name of
Registrant as Specified in
Charter) |
| New York |
|
000-19034 |
|
13-3444607 |
| (State or other jurisdiction
of |
|
(Commission File No.) |
|
(IRS Employer Identification
No.) |
| Incorporation) |
|
|
|
|
| 777 Old Saw Mill River Road, Tarrytown,
New York 10591-6707 |
| (Address of principal executive offices,
including zip code) |
| |
| (914) 347-7000 |
| (Registrant's telephone number, including area
code) |
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
| c |
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
|
|
|
|
| c |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
|
|
|
|
| c |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
| c |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
On May 12, 2010, Regeneron Pharmaceuticals, Inc. issued a press release
reporting preliminary clinical trial results for two antibody product candidates
in development, REGN727, a fully human antibody that targets Proprotein
Convertase Subtilisin/Kexin type 9 (PCSK9), and REGN475, a fully human antibody
that targets nerve growth factor (NGF). A copy of this press release is filed as
Exhibit 99.1 to this Form 8-K and is incorporated herein by
reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated May 12, 2010.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| Date: May 13, 2010 |
REGENERON PHARMACEUTICALS,
INC. |
| |
| |
| |
By: |
/s/ Stuart Kolinski |
| |
|
Name: |
Stuart Kolinski |
| |
|
Title: |
Senior Vice President and General
Counsel |
Exhibit
Index
| Exhibit
No. |
|
Description |
| 99.1 |
|
Press Release dated May 12,
2010. |